{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-058795","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-05-19T14:32:30+00:00","discovered_at":"2026-05-19T14:34:00.243259+00:00","generated_at":"2026-05-19T14:44:19.365868+00:00","sec_items":["1.01","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company","bullets":["Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.","Concurrent $290M private placement led by Fairmount; funds operations through 2028.","Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.","Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.","Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-058795","json":"https://secwatch.observer/filing/0001213900-26-058795.json","markdown":"https://secwatch.observer/filing/0001213900-26-058795.md","text":"https://secwatch.observer/filing/0001213900-26-058795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea0291482-8k425_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T14:44:19.365868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9bca14692752c67f398aa575b5aab0a9ba123c8","claim":"InMed Pharmaceuticals Inc. entered into Agreement and Plan of Merger and Reorganization with Mentari Therapeutics, Inc. valued at equity value of $125,000,000 (effective 2026-05-19).","evidence_excerpt":"ub, the “ Merger Subs ”), and Mentari Therapeutics, Inc., a Delaware corporation (“ Mentari ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”), pursuant to which, among other matters","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/0001213900-26-058795-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Mentari Therapeutics, Inc."},{"label":"Value","value":"equity value of $125,000,000"},{"label":"Effective","value":"2026-05-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}